Navigation Links
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Date:9/21/2009

ROCKVILLE, Md., Sept. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

Neuralstem is the first company to commence a stem cell trial to treat ALS. The trial will study the safety of Neuralstem's cells and the surgical procedures and devices required for multiple injections of Neuralstem's cells directly into the grey matter of the spinal cord. The FDA's approval represents a significant step toward delivering regenerative medicine directly to damaged neural cells in humans. ALS affects roughly 30,000 people in the U.S., with about 7,000 new diagnoses per year.

Neuralstem CEO and President, Richard Garr, stated, "The beginning of our clinical trial program is a major step towards achieving Neuralstem's goal of treating ALS, a fatal neurodegenerative disease for which currently there is no effective treatment or cure. While this trial aims to primarily establish safety and feasibility data in treating ALS patients, we also hope to be able to measure a slowing down of the ALS degenerative process. This trial will be in the extremely capable hands of Dr. Eva L. Feldman, M.D., Ph.D., Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery, and Dr. Jonathan Glass, Director of the Emory Neuromuscular Laboratory and Director of the Emory ALS Center, world
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neuralstem Shares Accepted for Trading on Amex(R)
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
5. Neuralstem Sues StemCells, Inc. Over New Patent
6. Neuralstem Responds to New StemCells, Inc. Lawsuit
7. Neuralstem Fills Key Product Development Position
8. Neuralstem Reports Second Quarter Financial Results and Highlights
9. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
10. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
11. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 27, 2015 IDEXX Laboratories, Inc. (NASDAQ: ... clinics have submitted over 100,000 specimens to IDEXX Reference ... the first 10 days since the breakthrough kidney function ... is a leading cause of suffering and death in ... are consistent with generally accepted kidney disease prevalence data ...
(Date:7/24/2015)... (PRWEB) , ... July 24, 2015 , ... VetStem Biopharma, ... Center in support of stem cell therapy training and clinical opportunities. , “We are ... opportunity to veterinarians in the San Diego area. Stem cell therapy is an established ...
(Date:7/24/2015)... SAN FRANCISCO , July 24, 2015 ... is expected to reach USD 27.8 billion by ... 2015 to 2022, according to a new study by ... genomic sequencing methodologies is expected to result in significant ... is expected to augment adoption and usage rates of ...
(Date:7/23/2015)... ... July 23, 2015 , ... Science and technology continue ... new drug therapies and devices – according to Susan Chang, MD, director of the ... on how science and new technology are impacting the development of new treatments and ...
Breaking Biology Technology:Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3
... Company to Hold a Conference Call Tomorrow (Tuesday) at 8:30 am ... ... September 10 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: XTL; ... of Bicifadine - a serotonin,and norepinephrine reuptake inhibitor (SNRI) - for ...
... LONDON, Sept. 7 Chiltern, a leading global ... Richard Schulz,Chiltern,s Country Manager for the Czech Republic, ... The award ceremony was held in,London,s historic Gibson ... peers by a panel of judges who,reviewed his ...
... On Thursday, October,18, 2007, Wyeth (NYSE: WYE ) ... Company will hold a one-hour conference call with,research analysts ... Interested,investors and others may listen to the call live ... may be accessed by visiting our website,at http://www.wyeth.com ...
Cached Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... Looking into the brain is yielding vital clues to ... being presented today at the Seventh International Conference on ... held at 12:15 p.m., Thursday, June 7, have helped ... treatment of the disease. , The first study, presented ...
... crops may contribute to increased productivity in sustainable agriculture, ... 8 issue of the journal Science. The study ... field experiments all over the world, involving corn and ... insecticidal properties. The research was conducted by scientists ...
... In a way, nanotubes are nature’s smallest candles. , These ... so small that it takes about 100,000 laid side-by-side to ... last five years, scientists have discovered that some individual nanotubes ... in light. Some glow brightly. Others glow dimly. Some glow ...
Cached Biology News:Brain holds clues to bipolar disorder 2New study finds genetically engineered crops could play a role in sustainable agriculture 2Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 9(S)-HODE by ... the lipoxygenation of linoleic acid in both plants ... plaques, as an esterified component of membrane phospholipids ...
... 9(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 9(S)-HODE is produced by the lipoxygenation of ... has been detected in atherosclerotic plaques, as an ...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: